Source comparison
CJC-1295 no DAC & Ipamorelin: Protocol Comparison
Dosing Frequency 2–3x daily (short half-life) 2–3x daily (pulsatile GH release) 2–3x daily (synergistic) Stacking allows lower individual doses while maintaining pulse amplitude. Reduces side effect risk Typical Dose Range 100–200 mcg per injection 100–300 mcg
This comparison does not assign a generated winner or score.
- Dosing Frequency
- 2–3x daily (short half-life)
- 2–3x daily (pulsatile GH release)
- 2–3x daily (synergistic)
- Stacking allows lower individual doses while maintaining pulse amplitude. Reduces side effect risk
- Typical Dose Range
- 100–200 mcg per injection
- 100–300 mcg per injection
- 100 mcg CJC + 100–200 mcg Ipamorelin
- Combined protocol mimics natural GH secretion patterns more closely than either alone
- GH Pulse Amplitude
- Moderate (GHRH pathway only)
- Moderate (ghrelin pathway only)
- High (dual-pathway activation)
- Dual-pathway activation produces 3–5× greater GH release than single-agent protocols in clinical studies
- IGF-1 Elevation Timeline
- 6–8 weeks to therapeutic range
- 6–10 weeks to therapeutic range
- 4–6 weeks to therapeutic range
- Faster IGF-1 normalisation with combination therapy shortens time to visible body composition changes
- Side Effect Profile
- Rare: injection site reaction, transient flushing
- Rare: mild hunger increase post-injection
- Similar to monotherapy. No additive adverse events
- Combination therapy does not increase adverse event frequency vs monotherapy per published safety data